Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• In heavily treatment-experienced (HTE) individuals with multidrug-resistant (MDR) human immunodeficiency virus (HIV)-1, fostemsavir combined with optimized background therapy (OBT) demonstrated sustained virologic suppression over 96 weeks in the BRIGHTE trial. Fostemsavir had lower odds of achieving virologic suppression compared to lenacapavir (LEN) + optimized background regimen (OBR) (OR = 6.57; 95% confidence interval (CI) 1.34-32.28) and ibalizumab (IBA) + OBR (OR = 8.93; 95% CI 2.07-38.46).
• Fostemsavir combined with N = 40 (OBT) significantly increased + (CD4) cell counts, with an increase of 135.78 cells/mm³ (95% CI 91.93-179.63, P < 0.001) compared to OBT alone at week 96, as seen in the BENCHMRK-1/-2 trial.
• The BRIGHTE trial did not provide specific adverse event rates or safety outcomes for fostemsavir combined with OBT, but comparisons of safety data between fostemsavir and other regimens were indirectly analyzed, adjusting for demographic and baseline characteristics.
• The population targeted in the studies consisted of HTE individuals with MDR HIV-1. These individuals demonstrated significant virologic and immunologic responses with fostemsavir combined with OBT, highlighting its importance in patients with limited treatment options due to resistance. Adjustments were made in the analyses to balance populations across trials based on demographic and baseline characteristics.